GlassScriptPhysician profile
Charles G Ray
NPI 1356348429
$4,869.94
in general payments reported to CMS, 2019-2025
38 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 78% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $211 · 2021: $246 · 2022: $675 · 2023: $667 · 2024: $660 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $606.31 | 2021-2025 | Lithovue, General - Kidney Stone Disease, Lumenis Pulse 120h |
| Sumitomo Pharma America, INC. | $556.88 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $545.42 | 2019-2025 | Xtandi |
| Abbvie INC. | $379.73 | 2019-2025 | |
| Medtronic, INC. | $312.34 | 2021-2025 | Interstim, Altaviva |
| Pfizer INC. | $303.90 | 2019-2025 | |
| Axonics, INC. | $236.01 | 2022-2024 | Axonics |
| Antares Pharma, INC. | $202.43 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Telix Pharmaceuticals | $177.98 | 2024-2025 | Illuccix |
| Accord Healthcare, INC. | $154.44 | 2024-2025 | |
| Janssen Biotech, INC. | $154.18 | 2019-2025 | Erleada |
| Neotract INC. | $149.80 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Urogen Pharma, INC. | $87.89 | 2022-2024 | Jelmyto |
| Ferring Pharmaceuticals INC. | $81.30 | 2019-2025 | Adstiladrin |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $75.16 | 2025 | Cvac Aspiration System |
| Novartis Pharmaceuticals Corporation | $71.72 | 2025 | |
| Sun Pharmaceutical Industries INC. | $63.57 | 2022-2023 | Yonsa |
| Halozyme INC | $57.10 | 2023 | |
| Endo USA, INC. | $49.78 | 2025 | Xiaflex |
| Verity Pharmaceuticals INC. | $48.54 | 2025 | Trelstar |
| 180 Medical, INC. | $46.58 | 2020-2023 | |
| Blue Earth Diagnostics | $46.01 | 2019 | |
| Myovant Sciences INC. | $43.44 | 2022 | |
| Endo Pharmaceuticals INC. | $43.08 | 2019 | |
| Urovant Sciences INC | $41.12 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.58 | 2020 | |
| Ambu INC. | $21.73 | 2025 | |
| Cycle Pharmaceuticals INC | $19.89 | 2025 | Venxxiva |
| Innovation Technologies INC | $18.29 | 2024 | Irrisept |
| Agiliti Surgical, INC. | $18.07 | 2025 | Koelis Trinity Mri/US Fusion |
| Azurity Pharmaceuticals, INC. | $17.21 | 2025 | Azmiro |
| Kowa Pharmaceuticals America, INC. | $17.21 | 2023 | Seglentis |
| Ethicon US, LLC | $16.69 | 2023 | Mega Soft |
| Coloplast Corp | $15.73 | 2025 | |
| Dentsply Ih INC. | $15.07 | 2019 | |
| Allergan, INC. | $13.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.